natgillin/translations-raw huggingface dataset:
The incidence of acute graft versus host disease (a-GVHD) data was collected in allogeneic patients (n=28).
Podatki o pojavnosti akutne reakcije presadka proti gostitelju (acute graft-versus-host disease – aGVHD) so bili zbrani pri alogenskih bolnikih (n = 28).
The incidence of acute graft versus host disease (a-GVHD) data was collected in OMC-BUS-4 study (allogeneic)(n=61) .
Podatki o pojavljanju akutne reakcije presadka proti gostitelju (acute graft-versus-host disease - aGVHD) so bili zbrani v raziskavi OMC-BUS-4 (alogenska) (n = 61).
The incidence of ADRs of all grades and grade 3 /4 ADR was similar in elderly patients compared to younger patients (<65 years).
Incidenca neželenih učinkov vseh stopenj ter učinkov 3. ali 4. stopnje je bila pri starejših bolnikih podobna kot pri mlajših (< 65 let).
The incidence of adverse events listed above have the potential to occur with a higher frequency in patients who have a poor performance status (see section 4.4).
Incidenca navedenih neželenih učinkov je lahko večja med bolniki s slabim stanjem zmogljivosti (glejte poglavje 4.4).
The incidence of adverse events listed above have the potential to occur with a higher frequency in patients who have a poor performance status (see section 4.4).
Incidenca zgoraj navedenih neželenih dogodkov je lahko večja pri bolnikih v slabšem stanju (glejte poglavje 4.4).
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients).
Pojavnost neželenih učinkov in laboratorijskih abnormalnosti (z izjemo povišanja ALT in CPK, glejte spodaj) je bila podobna pri bolnikih, ki so se zdravili s placebom, in pri tistih, ki so se zdravili z lamivudinom.
The incidence of adverse reactions in 384 subjects exposed to photodynamic therapy with Ameluz in pivotal clinical trials is listed below.
Pojavnost neželenih učinkov pri 384 bolnikih, izpostavljenih fotodinamičnemu zdravljenju z zdravilom Ameluz v osrednjih kliničnih preskušanjih, je navedena v spodnji preglednici.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury (see section 4.4).
Incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence, je bila povečana pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače (glejte poglavje 4.4).
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury (see section 4.4).
Pogostost neželenih učinkov na splošno, neželenih učinkov na osrednji živčni sistem in predvsem pojava zaspanosti se je povečala pri zdravljenju osrednje nevropatske bolečine po poškodbi hrbtenjače (glejte poglavje 4.4).
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence je bila zvečana pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence, je bila povečana pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Pogostost neželenih učinkov na splošno, neželenih učinkov na osrednji živčni sistem in predvsem pojava zaspanosti se je povečala pri zdravljenju osrednje nevropatske bolečine po poškodbi hrbtenjače.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače je bila zvečana incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence.
The incidence of AEs, including Grade  3 AEs and SAEs, was similar between the two treatment arms.
Incidenca neželenih učinkov, vključno z neželenimi učinki stopnje  3 in resnimi neželenimi učinki, je bila pri obeh zdravljenih skupinah podobna.
The incidence of all adverse events relating to liver and biliary systems was  1.5% in any treatment group and similar to placebo.
Incidenca vseh neželenih pojavov, povezanih s hepatobiliarnim sistemom, je bila v vseh zdravljenih skupinah < 1,5 % in podobna, kot pri placebu.
The incidence of all adverse events relating to liver and biliary systems was  1.5% in any treatment group and similar to placebo.
Pogostnost vseh neželenih učinkov, povezanih z jetri in žolčnim sistemom je bila < 1,5 % v katerikoli skupini zdravljenja in podobna pogostnosti pri placebu.
The incidence of all adverse events relating to liver and biliary systems was 1.5% in any treatment group and similar to placebo.
Incidenca vseh neželenih učinkov, povezanih z jetri in biliarnim sistemom je bila < 1,5 % v vseh skupinah in podobna kot pri placebu.
The incidence of all cause mortality at Day 30 was also significantly reduced from 8.9% for the control group to 7.8% in the fondaparinux group (hazard ratio 0.87, 95% CI, 0.77;0.98, p = 0.02).
Do 30. dne se je pomembno zmanjšala tudi smrtnost iz kateregakoli vzroka – z 8,9 % v kontrolni skupini na 7,8 % v skupini, ki je prejemala fondaparinuks (razmerje tveganja 0,87, 95 % interval zaupanja, 0,77;0,98, p = 0,02).
The incidence of angioedema in patients not taking concomitant ACE inhibitors was the same in both groups.
Pri bolnikih, ki niso sočasno jemali zaviralcev ACE, je bila pogostnost angioedema enaka v obeh skupinah.
The incidence of antibody titres in treated dogs under field conditions is low and the puppies will have no or very limited exposure to anti-BMP-2 antibodies due to the potential for limited transfer across the placenta in dogs.
Incidenca titrov protiteles pri zdravljenih psih na terenu je nizka, zaradi morebitnega omejenega prenosa protiteles skozi placento pri psih, mladiči protitelesom anti-BMP-2 ne bodo izpostavljeni oziroma bodo izpostavljeni v zelo omejenem obsegu.
The incidence of any adverse reaction(s) may increase as the trough sirolimus level increases.
Incidenca kateregakoli neželenega učinka se lahko zveča z zvišanjem najnižje koncentracije sirolimusa.
The incidence of application site skin reactions leading to discontinuation was higher in the Asian population with 4.9% and 8.4% in the Chinese and Japanese population respectively.
V azijski populaciji pa je bila pogostnost reakcij na mestu aplikacije, zaradi katerih je bilo treba zdravljenje prekiniti, večja – v kitajski populaciji je znašala 4,9 %, v japonski populaciji pa 8,4 %.
The incidence of binding antibodies (excluding predose positive patients) was 1% as detected by the acid-dissociation ELISA and < 1% as detected by the Biacore assay;
Incidenca protiteles, ki vežejo panitumumab (izključeni bolniki, pozitivni pred odmerkom) je bila s kislinsko-disociacijskim ELISA 1 % in s preizkusom »Biacore« < 1 %.
The incidence of both ACUITY-scale and TIMI-scale bleeding events up to day 30 for the intent-to- treat population is presented in Table 6.
Pogostnost krvavitev po lestvici ACUITY in lestvici TIMI do 30. dne je za celotno populacijo predstavljena v tabeli 6.
The incidence of clinical fractures, including vertebral, non-vertebral and hip fractures, was evaluated in 2,127 men and women aged 50-95 years (mean age 74.5 years) with a recent (within 90 days) low- trauma hip fracture who were followed for an average of 2 years on study medication.
Incidenco kliničnih zlomov, vključno z zlomi vretenc, nevretenčnimi zlomi in zlomi kolka, so vrednotili pri 2.127 moških in ženskah, starih 50-95 let (povprečna starost 74,5 let) z nedavnim (v okviru 90 dni) zlomom kolka po lažji poškodbi, ki so jih opazovali povprečno 2 leti med zdravljenjem s študijskim zdravilom.
The incidence of clinical worsening by week 16 in patients treated with tadalafil 40 mg (5 %; 4 of 79 patients) was less than placebo (16 %; 13 of 82 patients).
Pogostnost kliničnega poslabšanje do 16 tedna je bila nižja pri bolnikih, ki so dobivali tadalafil 40 mg (5 %; 4 od 79 bolnikov) kot pri bolnikih, ki so prejemali placebo (16 %; 13 od 82 bolnikov).
The incidence of CNS bleeds during the 28-day study period was 0.2% and 0.1% for drotrecogin alfa (activated)- treated and placebo-treated patients, respectively.
Incidenca krvavitev v osrednje živčevje v 28-dnevnem trajanju študije je bila 0,2 % oziroma 0,1 % pri bolnikih, zdravljenih z drotrekoginom alfa (aktiviranim), oziroma bolnikih, ki so prejemali placebo.
The incidence of CNS bleeds during the 28-day study period was 6 (0.5%) and 5 (0.4%) for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively.
Incidenca krvavitev v osrednje živčevje v 28- dnevnem trajanju študije je bila 6 (0,5 %) oziroma 5 (0,4 %), pri bolnikih, zdravljenih z drotrekoginom alfa (aktiviranim), oziroma bolnikih, ki so prejemali placebo.
The incidence of confirmed hypoglycaemia was uncommon for Onglyza 5 mg (0.8%) and placebo (0.7%).
Incidenca potrjene hipoglikemije je bila občasna za zdravilo Onglyza 5 mg (0,8 %) in placebo (0,7 %)
The incidence of DAGT seroconversion in patients receiving ceftolozane/tazobactam was 0.2% in the clinical trials.
Pojavnost serokonverzije DAGT pri bolnikih, ki so prejemali ceftolozan/tazobaktam, je bila v kliničnih preskušanjih 0,2 %.
The incidence of diarrhoea, dizziness, asthenia, weight decrease, and dehydration was increased by ≥5% in older people compared to younger patients.
Incidenca driske, omotice, astenije, zmanjšanja telesne mase in dehidracije je bila pri starejših bolnikih za ≥ 5 % večja kot pri mlajših.
The incidence of diverticulitis was comparable between treatment groups in postmenopausal women or men with osteoporosis and in women undergoing aromatase inhibitor therapy for nonmetastatic breast cancer.
V terapevtskih skupinah žensk po menopavzi ali moških z osteoporozo in žensk, ki so se zdravile z zaviralcem aromataze zaradi nemetastatskega raka dojke, je bila incidenca divertikulitisa primerljiva.
The incidence of documented symptomatic hypoglycaemia when dulaglutide 1.5 mg was used with sulphonylurea alone was 11.3% and the rate was 0.90 events/patient/year, and there were no episodes of severe hypoglycaemia.
Pogostnost dokumentirane simptomatske hipoglikemije ob uporabi dulaglutida 1,5 mg s samo sulfonilsečnino je bila 11,3 %, stopnja pa 0,90 dogodkov/bolnika/leto; epizod hude hipoglikemije ni bilo.
The incidence of efficacy failure at 12 months (defined as death, graft loss, biopsy-confirmed acute rejection, or lost to follow-up) was 14.0% in the Advagraf group (N=214), 15.1% in the Prograf group (N=212) and 17.0% in the ciclosporin group (N=212).
V skupini, ki je prejemala zdravilo Advagraf (n = 214), je bila izguba učinkovitosti po 12 mesecih (definirana kot smrt, odmrtje presadka, z biopsijo potrjena akutna zavrnitev ali izguba podatkov o spremljanju bolnika) 14,0-odstotna, v skupini, ki je prejemala zdravilo Prograf (n = 212), 15,1-odstotna, v skupini, ki je prejemala ciklosporin (n = 212), pa 17,0-odstotna.
The incidence of endometrial hyperplasia was 0.3% (1 case out of 317 biopsies) after 1 year of treatment with an upper 95% confidence limit of 1.74% (see section 5.1).
Incidenca hiperplazije endometrija je bila 0,3% (1 primer na 317 biopsij) po 1 letu zdravljenja z zgornjo 95-odstotno mejo zaupanja 1,74% (glejte poglavje 5.1).
The incidence of erythema multiforme or
1,7 % jih je zaradi izpuščaja zdravljenje prekinilo.
The incidence of erythema multiforme or Stevens- Johnson syndrome was approximately 0.1%.
Pojavnost multiformnega eritema ali Stevens-Johnsonovega sindroma je bila približno 0,1 %.
The incidence of fatal ATEs was 0.6% in the experimental arm versus 0.2% in the control arm (see also section 4.4).
Incidenca smrtnih arterijskih trombemboličnih dogodkov je bila 0,6 % v skupini eksperimentalnega zdravljenja v primerjavi z 0,2 % v kontrolni skupini (glejte tudi poglavje 4.4).
The incidence of fever and documented infections were not reduced in either setting.
V nobenem izmed omenjenih stanj pa zdravljenje s filgrastimom ni vplivalo na zmanjšanje pogostnosti zvišane telesne temperature in zabeleženih okužb.
The incidence of fractures was 8 for zoledronic acid- treated patients versus 7 for risedronate-treated patients (p=0.8055).
V skupini z zoledronsko kislino je bila incidenca zlomov 8 v primerjavi z incidenco 7 v skupini z risedronatom (p = 0,8055).
The incidence of fractures was 8 for zoledronic acid-treated patients versus 7 for risedronate-treated patients (p=0.8055).
V skupini z zoledronsko kislino je bila incidenca zlomov 8 v primerjavi z incidenco 7 v skupini z risedronatom (p=0,8055).
The incidence of gastrointestinal events (e.g. diarrhoea [14% versus 10%], nausea [12% versus 9%], upper abdominal pain [10% versus 6%], abdominal pain [9% versus 4%], vomiting [8% versus 5%] and dyspepsia [5% versus 3%]) was increased in patients treated with Tecfidera compared to placebo, respectively.
Incidenca prebavnih pojavov (npr. driska [14 % v primerjavi z 10 %], navzea [12 % v primerjavi z 9 %], bolečina v zgornjem delu trebuha [10 % v primerjavi s 6 %], bolečina v trebuhu [9 % v primerjavi s 4 %], bruhanje [8 % v primerjavi s 5 %] in dispepsija [5 % v primerjavi s 3 %]) je bila večja pri bolnikih, zdravljenih z zdravilom Tecfidera, kot pri bolnikih, zdravljenih s placebom.
The incidence of Grade 3 hand-foot skin reaction in Asians was 28.4% (CRC) and 23.5% (GIST) (see sections 4.2 and 4.4).
Incidenca kožnih reakcij na dlaneh in podplatih stopnje 3 pri bolnikih azijske rase je bila 28,4 % pri bolnikih s kolorektalnim rakom in 23,5 % pri bolnikih z GIST (glejte poglavji 4.2 in 4.4).
The incidence of Grade 3 hypertension was 7.6% (CRC) and 27.3% (GIST).
Incidenca hipertenzije stopnje 3 je bila 7,6 % (metastatski kolorektalni rak) in 27,3 % (GIST).
The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8).
Bolnice, ki so doživele zapleteno nevtropenijo (febrilna nevtropenija, dolgotrajna nevtropenija ali okužba), so kot sekundarno profilakso dobile G- CSF.
The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8).
Incidenca nevtropenije, febrilne nevtropenije in nevtropeničnih okužb 4. stopnje se je zmanjšala pri bolnicah, ki so prejemale primarno profilakso z G- CSF (glejte poglavje 4.8).
The incidence of haemorrhagic events (11% G+B, 10% B) and Grade 3-5 haemorrhagic events (5% G+B, 3%B) was similar in both treatment arms with no fatal events reported.
Incidenca hemoragičnih dogodkov (v skupini G + B 11 %, v skupini z B pa 10 %) in hemoragičnih dogodkov 3. do 5. stopnje (v skupini G + B 5 %, v skupini B pa 3 %) je bila v obeh zdravljenih skupinah podobna, o učinkih s smrtnim izidom pa niso poročali.
The incidence of hepatic transaminase increases was greater in patients receiving Plegridy compared to placebo.
Incidenca zvišanja jetrne transaminaze je bila večja pri bolnikih, ki so prejemali zdravilo Plegridy, v primerjavi s placebom.
The incidence of hepatotoxicity varies considerably and can occur with any dose but more frequently when the recommended dose is exceeded.
Pojavnost hepatotoksičnosti se bistveno razlikuje in se lahko pojavi pri katerem koli odmerku, vendar je pogostejša ob prekoračitvi priporočenega odmerka.
The incidence of herpes zoster among patients in the B+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.
V skupini, zdravljeni z B+M+P, je pri 17% bolnikov, ki niso prejemali protivirusnih zdravil, prišlo do reaktivacije virusa herpes zoster, pri bolnikih, ki so prejemali protivirusna zdravila, pa je prišlo do reaktivacije virusa pri 3% bolnikov.
The incidence of herpes zoster among patients in the BR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).
Pogostnost virusa herpes zoster v skupini BR-CAP je bila 10,7% pri bolnikih, ki niso prejemali protivirusnih zdravil, pri bolnikih, ki so prejemali protivirusna zdravila pa 3,6% (glejte poglavje 4.4).
The incidence of herpes zoster among patients in the Bzmb+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.
V skupini, zdravljeni z Bzmb+M+P, je prišlo do reaktivacije virusa herpes zoster pri 17 % bolnikov, ki niso prejemali protivirusnih zdravil, pri bolnikih, ki so prejemali protivirusna zdravila, pa je prišlo do reaktivacije virusa pri 3 % bolnikov.
The incidence of hospitalisations and IV anti-infective use associated with a clinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo (1% versus 14%, p0.001; and 2% versus 10%, p0.001)
Med prejemnicami pegfilgrastima je bila tudi manjša incidenca hospitalizacij in intravensko uporabljene antiinfektivne terapije, povezanih s klinično diagnozo febrilne nevtropenije, kot med prejemnicami placeba (1 % v primerjavi s 14 %, p < 0,001, ter 2 % v primerjavi z 10 %, p < 0,001).
The incidence of hypersensitivity reactions was 1.1% in both Onglyza-treated patients and placebo- treated patients.
Incidenca preobčutljivostnih reakcij je bila 1,1 % tako pri bolnikih, ki so prejemali zdravilo Onglyza, kot pri tistih, ki so prejemali placebo.
The incidence of hypersensitivity reactions was 1.1% in both saxagliptin-treated patients and placebo-treated patients.
Incidenca preobčutljivostnih reakcij je bila 1,1 % tako pri bolnikih, ki so prejemali saksagliptin, kot pri tistih, ki so prejemali placebo.
The incidence of hypoglycaemia was increased when prolonged-release exenatide was used in combination with a sulphonylurea (24.0 % versus 5.4 %) (see section 4.4).
Incidenca hipoglikemije je bila zvišana ob uporabi eksenatida v obliki s podaljšanim sproščanjem v kombinaciji s sulfonilsečnino (24,0 % proti 5,4 %) (glejte poglavje 4.4).
The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs.
Pogostnost hipoglikemij je bila manjša v skupini z vildagliptinom kot v skupini s placebom (22,9 % v primerjavi z 29,6 %).
The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo.
Pojavnost hipoprolaktinemije ali znižane ravni prolaktina v serumu pri bolnikih, zdravljenih z aripiprazolom, je bila 0,4 % v primerjavi s skupino s placebom (0,2 %).
The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4%, compared with 0.02% for patients treated with placebo.
Pojavnost hipoprolaktinemije ali znižane ravni prolaktina v serumu pri bolnikih, zdravljenih z aripiprazolom, je bila 0,4 % v primerjavi s skupino s placebom (0,2 %).
The incidence of ILD was 6.2% in patients of Japanese ethnicity, 1.2% in patients of Asian ethnicity and 2.4% in non-Asian patients. (See Section 4.8).
Pojavnost IBP je bila pri bolnikih japonske etnične pripadnosti 6,2 %, pri bolnikih azijske etnične pripadnosti 1,2 % in pri neazisjkih bolnikih 2,4 % (glejte poglavje 4.8).
The incidence of infection was 38% in the Gazyvaro plus chlorambucil arm and 37% in the rituximab plus chlorambucil arm (with Grade 3-5 events reported in 12% and 14%, respectively and fatal events reported in < 1% in both treatment arms).
Incidenca okužb je bila s kombinacijo zdravila Gazyvaro in klorambucila 38-% in s kombinacijo rituksimaba in klorambucila 37-% (neželene učinke od 3. do 5. stopnje so zabeležili pri 12 % bolnikov v prvi skupini in 14 % v drugi skupini, učinkov s smrtnim izidom pa je bilo v obeh skupinah < 1 %).
The incidence of infection was 65% in the G+B arm and 56% in the B arm (with Grade 3-5 events reported in 18% and 17%, respectively, and fatal events reported in 5 patients (3%) in the G+B and 7 patients (4%) in the B arm).
Incidenca okužb je bila v skupini G + B 65 %, v skupini z B pa 56 % (neželene učinke od 3. do 5. stopnje so zabeležili pri 18 % bolnikov v prvi skupini in 17 % v drugi skupini, o učinku s smrtnim izidom pa so poročali pri 5 bolnikih (3 %) v skupini G + B in 7 bolnikih (4 %) v skupini B.
The incidence of infections leading to dose interruptions was also numerically higher in patients weighing <30 kg treated with 10 mg/kg tocilizumab (21.4%) compared to patients weighing ≥30 kg, treated with 8 mg/kg tocilizumab (7.6%).
Incidenca okužb, ki so vodile v prekinitev odmerjanja, je bila prav tako številčno višja pri bolnikih s telesno maso < 30 kg, ki so se zdravili z 10 mg/kg tocilizumaba (21,4 %) v primerjavi z bolniki s telesno maso ≥ 30 kg, ki so se zdravili z 8 mg/kg tocilizumaba (7,6 %).
The incidence of infusion-related symptoms decreased substantially with subsequent infusions and is <1% of patients by the eighth cycle of MabThera-containing treatment.
Incidenca simptomov in znakov, povezanih z infuzijo, se je z nadaljnjimi infuzijami precej zmanjšala in je bila do osmega cikla zdravljenja z zdravilom MabThera < 1 %.
The incidence of infusion-related symptoms decreases substantially with subsequent infusions and is less than 1% after eight doses of MabThera.
Incidenca simptomov, povezanih z infuzijo, se z nadaljnjimi infuzijami bistveno zmanjšuje in je po osmih odmerkih zdravila MabThera manjša kot 1 %.
The incidence of injection site reactions may be reduced by the use of an auto-injector.
Pogostnost reakcij na mestu aplikacije se lahko zmanjša z uporabo avtoinjektorja.
The incidence of IRRs in subsequent infusions was comparable in both arms and decreased with each cycle.
V nadaljnjih infundiranjih je bila incidenca reakcij, povezanih z infuzijo, primerljiva v obeh skupinah in z vsakim ciklusom manjša.
The incidence of IRRs was 65% with the infusion of the first 1,000 mg of Gazyvaro (20% of patients experiencing a Grade 3-5 IRR, with no fatal events reported).
Incidenca reakcij, povezanih z infuzijo, je bila 65-% med infundiranjem prvih 1000 mg zdravila Gazyvaro (20 % bolnikov je imelo reakcijo, povezano z infuzijo od 3. do 5. stopnje, smrtnih primerov ni bilo).
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any conditions associated with hypoxia.
Pojavnost laktacidoze je mogoče in tudi potrebno zmanjševati z oceno drugih povezanih dejavnikov tveganja, kot so slabo urejena sladkorna bolezen, ketoza, dolgotrajno stradanje, čezmerno uživanje alkohola, okvara jeter in vsa stanja, povezana s hipoksijo.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Incidenco laktacidoze je mogoče in jo je treba zmanjšati tudi z ugotavljanjem drugih spremljajočih dejavnikov tveganja, npr. slabe urejenosti sladkorne bolezni, ketoze, dolgotrajnega posta, čezmernega uživanja alkohola, insuficience jeter in vseh motenj, povezanih s hipoksijo.